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BACKGROUND: Coxsackie and adenovirus receptor (CAR) has been suggested to function as a tumour suppressor. Its impact on the
adenoma–carcinoma sequence of the colon, however, is unclear.
METHODS: Coxsackie and adenovirus receptor was analysed in non-cancerous and neoplastic colon samples using immunohis-
tochemistry and quantitative RT–PCR. The function of CAR in colon cancer cell lines was determined following application of CAR
siRNA or ectopic expression of a human full-length CAR cDNA.
RESULTS: Compared with healthy mucosa, increased CAR-mRNA expression was found in adenomas, whereas primary cancers and
metastases displayed a marked decline. At the plasma membrane, CAR was present in normal mucosa samples (93%), adenomas,
and metastases (100% ea.), whereas in colon cancers, it was found less frequently (49%, Po0.0001). Cytoplasmic CAR
immunopositivity increased from normal mucosa (22%), to adenomas (73%, P¼0.0006), primary cancers (83%, Po0.0001), and
metastases (67%, P¼0.0019). In cancer cell lines, CAR inhibition resulted in increased proliferation, whereas enforced ectopic CAR
expression led to opposite results. Blocking the extracellular portion of CAR increased cell invasion in vitro. In mice, xenotransplants of
colon cancer cells with enforced CAR expression formed significantly smaller tumours, whereas CAR inhibition increased the
formation of liver metastases.
CONCLUSION: We conclude that CAR facilitates complex effects during colon carcinogenesis, potentially mediated by its stage-
dependent subcellular distribution; high CAR expression potentially prevents apoptosis in adenomas, loss of CAR at the plasma
membrane promotes growth, and dissemination of primary cancers, and high membranous CAR presence may support the
establishment of distant metastases.
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Colon cancer represents one of the leading cancer entities
worldwide (Parkin et al, 2005). It most commonly develops from
adenomas, referred to as ‘adenoma–carcinoma sequence’ (Cho
and Vogelstein, 1992). The clinical outcome of colon cancer is
critically determined by local tumour growth, as well as by the
presence of local and distant metastases. For both, invasion and
metastatic spread, an impaired adhesion of cancer cells is
considered as a crucial prerequisite. Although previously studied,
particularly for the adherens junction protein E-cadherin (Buda
and Pignatelli, 2004), investigation of tight junctions (TJs) in colon
cancer has turn out to be of interest in recent years. Tight
junctions represent a complex of proteins in epithelial and
endothelial cells separating the apical and basolateral plasma
membrane (Satoh et al, 1996; Tsukita et al, 1996). They maintain
cellular polarity as well as tissue integrity, and regulate the
paracellular transport (Tsukita and Furuse, 2000). An impaired
TJ barrier has been found in human colon adenomas and in the
‘pre-neoplastic’ colon of rats treated with the carcinogen 1,
2-dimethylhydrazine (DMH) (Soler et al, 1999). In colon
cancer, a decreased presence of TJ proteins has been described
for instance for ZO-1, occludin, and claudin 8, in part, correlating
with poor cancer differentiation, disease recurrence, and
an adverse prognosis (Kimura et al, 1997; Resnick et al, 2005;
Grone et al, 2007). In contrast, TJ protein upregulation in
colon cancers compared with normal colon mucosa has been
noted for instance for claudins 1 and 12 (Miwa et al, 2000;
Grone et al, 2007). These observations point to a complex
dysregulation of TJ proteins in colon carcinogenesis. The
functional role of this phenomenon, however, has rarely
been investigated: Claudin 1 has been shown to induce
epithelial–mesenchymal transdifferentiation in cultured human
colon cancer cell lines, to promote the growth of xenograft
tumours and the formation of metastases in athymic mice
(Dhawan et al, 2005). A more detailed understanding of the
function of TJs in colon cancer, however, is still missing.
The coxsackie adenovirus receptor (CAR), a transmembrane
glycoprotein, was initially characterised as a viral attachment site
on the surface of epithelial cells (Bergelson et al, 1997). Later on it
was identified as a component of the TJ complex, an interacting
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spartner for a number of TJ proteins, and a regulator of TJ
formation (Cohen et al, 2001; Sollerbrant et al, 2003; Coyne et al,
2004; Excoffon et al, 2004; Mirza et al, 2005; Raschperger et al,
2006). In the context of malignant diseases, reduced CAR presence
was found in several solid cancers partially associated with poor
differentiation, increased infiltration, and an unfavourable clinical
outcome (Rauen et al, 2002; Sachs et al, 2002; Matsumoto et al,
2005; Korn et al, 2006; Buscarini et al, 2007; Okegawa et al, 2007;
Anders et al, 2009b). In primary colon cancers, a high variability in
CAR expression was found, with approximately 75% of the cases
showing CAR downregulation in (Zhang et al, 2008). Functionally,
loss of CAR has been suggested to weaken intercellular adhesion,
to increase proliferation, and to promote migration as well as
invasion of cancer cells (Okegawa et al, 2000, 2001; Bruning and
Runnebaum, 2003, 2004; Huang et al, 2005; Wang et al, 2005;
Anders et al, 2009a,b). Recently, we demonstrated that down-
regulation of a-catenin following reduced expression of CAR
substantially contributes to these phenomena (Stecker et al, 2009).
On the basis of these findings, a tumour-suppressive role of CAR
in human cancers has been postulated. In contrast, it has also been
speculated that CAR advances the development of adenocarcino-
mas, as elevated CAR expression was found in early-stage breast
and oesophageal cancer (Anders et al, 2003b; Kuster et al, 2010).
Moreover, it has been demonstrated that CAR protects adeno-
carcinoma cells against apoptosis and is needed for efficient
tumour formation (Qin et al, 2004; Bruning et al, 2005).
Prompted by these findings, suggestive of a complex role of CAR
in carcinogenesis, we aimed to clarify the influence of CAR on the
pathobiology of colon cancers. We determined CAR presence in
the course of the adenoma–carcinoma sequence and studied CARs
function in vitro and in vivo using cultured colon cancer cell lines,
following ectopically regulated CAR expression.
MATERIALS AND METHODS
Study population and tissues
Tissue samples were obtained from 82 patients (43 men, mean
age 70 years; range: 43–91 years) comprehending normal colon
mucosa (n¼27), tubular adenomas (n¼22), primary colon
adenocarcinomas (n¼53), and metastatic colon cancers (total
n¼22: liver n¼6, lung n¼4, lymph nodes n¼12). Staging and
diagnosis was assessed according to the WHO classification
(Hamilton, 2000) and the TNM staging, set out by the International
Union against cancer (Wittekind, 2003).
Quantitative mRNA determination
Total RNA was isolated from three consecutive 15-mm tissue
sections containing at least 80% of the tissue of interest using the
ABSOLUTELY RNA FFPE KIT (Stratagene, Amsterdam, The
Netherlands) according to the manufacturer’s protocol. Upon
reverse transcription of 50ng of total RNA with random hexamer
primers using the ‘first-strand synthesis system for RT–PCR’
(Invitrogen, Karlsruhe, Germany), real-time quantification was
carried out as described previously (Anders et al, 2003b) on a
Stratagene MX3000P cycler. Quantification was assessed by the
comparative DCT method normalising CT values to b-actin.
Complementary DNA derived from Chinese hamster ovary cells
(CHO, CHO-CAR; a kind gift of Dr J Bergelson, Division of
Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia,
PA, USA) was used as negative and positive control, respectively.
Immunohistochemistry
Immunohistochemical staining was carried out as described
previously (Anders et al, 2009b). In brief, tissue sections were
deparaffinised, rehydrated, and submitted to antigen retrieval by
microwave treatment. Anti-CAR (H-300: sc-15405, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA; 1:50) served as primary
antibody. A biotinylated goat anti-rabbit immunoglobulin (Vector
Laboratories, Burlingame, CA, USA; 1:400) was used as secondary
antibody, followed by treatment with streptavidin-biotinylated
horseradish peroxidase complex (Vectastain Elite ABC kit,
Vector Laboratories). Using diaminobenzidine tetrahydrochloride
(Sigma-Aldrich, Munich, Germany), sections were developed and
counterstained with haematoxylin. Staining results for CAR were
evaluated by estimating the percentage of epithelial cells showing
specific immunoreactivity by an expert pathologist (MV) who was
blinded for the clinical data. Immunopositivity at the plasma
membrane and in the cytoplasm was assessed separately. The CAR
status was classified as: negative (no immunoreactivity), weak
(0–5% positive cells), moderate (5–50% positive cells), or strong
(450% positive cells). Only samples showing moderate or strong
immunoreactivity were considered positive.
Cell culture and generation of stably transfected cell lines
Human colon cancer cell lines SW480, SW620, DLD1, and HCT116
were obtained from the American Type Culture Collection
(Rockville, MD, USA) and from the ‘Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH’ (Braunschweig,
Germany), respectively, and cultured in the recommended growth
media. Chinese hamster ovary cells were cultured in Ham’s F12
containing 10% FCS. Colon cancer cell lines with functional CAR
knocked down by specific CAR siRNAs or ectopic expression by
human full-length CAR cDNA expressed under control of the CMV
promoter in a pcDNA3.1 expression vector (‘hCARpcDNA3.1’; a
kind gift of Dr J Bergelson), were generated as described previously
(Anders et al, 2009b). Expression of CAR in pooled cell
populations was determined by western blotting, and FACS was
used for the assessment of CAR presence at the cell surface.
Western blotting
Protein lysates were obtained as previously described (Anders
et al, 2003a). Subsequently, equal amounts of protein lysates were
loaded on reducing Laemmli gels, immunoblotted with specific
antibodies against CAR (H-300: sc-15405, Santa Cruz Biotechnol-
ogy), or b-actin (Sigma-Aldrich), and detected using the ECL
system (Amersham Pharmacia, Piscataway, NJ, USA). Protein
lysates of CHO and CHO-CAR cells were used as negative and
positive controls, respectively.
Measurement of CAR cell surface expression
Expression of CAR cell surface was analysed as previously
described (Anders et al, 2003a). In brief, living cells were incubated
with the anti-CAR antibody RmcB (a kind gift of Dr J Bergelson) in
binding buffer (PBS containing 2% BSA and 10% normal goat
serum) at 41C for 45min. Afterwards, cells were incubated with a
Cy-3-conjugated anti-mouse antibody (Molecular Probes, Eugene,
OR, USA). Analysis of stained cells was performed on a FACS-
Calibur cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
Assessment of colon cancer cell proliferation in vitro and
in vivo
Cells were seeded onto six-well plates (n¼3 10
5 cells per well) in
the recommended growth media containing 10% FCS. After 48h,
cells were detached using trypsin and counted using a haemato-
cytometer (VWR International, Darmstadt, Germany). All experi-
ments were performed in triplicate and repeated at least twice. To
determine colon cancer cell growth in vivo,1 0
7 cells were injected
subcutaneously into both flanks of 6- to 8-week-old male NOD/
SCID mice obtained from The Jackson Laboratory (Bar Harbor,
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sME, USA). Tumour volumes were measured twice per week from
day 8 onwards with a calliper in two dimensions and calculated
according to volume¼length wide
2/2. All animal experiments
were performed according to German law at the ‘Experimental
Pharmacology & Oncology GmbH (Berlin-Buch, Germany).
Cell invasion into matrigel
Cells cultured in media with or without the anti-CAR antibody
RmcB (a kind gift of Dr J Bergelson) were seeded onto the top of
‘BioCoat Matrigel Invasion Chambers’ (BD Biosciences, Bedford,
MA, USA) containing 8-mm pore size PET membranes covered
with matrigel matrix. Medium containing 10% FCS was added to
the bottom well of the chambers as a chemoattractant, whereas
serum-free medium was used as a control. Following 48h at 371C
and 5% CO2, cells invaded the matrigel-coated membrane, located
at the lower membrane surface, were fixed, and stained by crystal
violet containing 10% ethanol. Cells of three representative areas in
each well were counted at a magnification of  100. Experiments
were performed in triplicate and repeated at least twice.
Colon cancer cell metastasis in vivo
The impact of CAR inhibition on the metastatic behaviour of colon
cancer cells was assessed in 6-week-old female athymic SCID mice
obtained from Charles River Laboratories (Sulzfeld, Germany). All
mice received injections of 1 10
6 cells (SW480 following CAR
inhibition, SW620 with CAR upregulation or the respective
controls) into the spleen. At 4 weeks, all mice were killed and
spleen, liver, lung, and paraaortic lymph nodes were obtained,
fixed in formalin, and embedded in paraffin. Subsequent
histopathological analyses were undertaken using haematoxylin
and eosin stained sections. All animal experiments were approved
by the local governmental authorities (Landesamt fu ¨r Gesundheit
und Soziales, Berlin, Germany).
Induction of apoptosis
To assess caspase activity, colon cancer cells were grown in 1 10
4
96-well culture plates. After 24h of incubation, apoptosis was
induced by addition of 50ngml
 1 TRAIL (Biomol, Hamburg,
Germany). Following another 48h, caspase-3/7 activity was
determined using Caspase-Glo 3/7 Assay Systems (Promega,
M a n n h e i m ,G e r m a n y )a t1 ,2 ,a n d3ha f t e ra d d i t i o no fC a s p a s e - G l o
3/7 on a luminescence reader (Mithras LB 940, Berthold
Technologies GmbH & Co. KG, Bad Wildbad, Germany). Here-
after, cell numbers were assessed photometrically following
addition of crystal violet (Spectramax 340 PC Microplate Reader,
Molecular Devices, Sunnyvale, CA, USA). All experiments were
performed in triplicate and repeated at least twice.
Statistical analysis
Statistical calculations were performed with the GraphPad Prism
software (version 4.00; GraphPad Software, Inc., San Diego, CA,
USA) using the t-test or w
2-test, when applicable.
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Figure 1 Presence and distribution of CAR in non-transformed colon
mucosa, adenomas, primary, and metastatic colon cancers. Real time
RT–PCR data represent median CAR mRNA expression level of non-
transformed mucosa, adenomas, primary colon cancers, and metastases
displaying highest CAR expression in adenomas (A). Immunohistochem-
istry revealed abundant CAR presence at the plasma membrane (black
bars) in non-transformed mucosa samples, adenomas, primary colon
cancer, and metastases. In colon cancers, a significant decrease of
membranous CAR immunoreactivity was found. Cytoplasmic CAR
immunopositivity (grey bars) was observed significantly more often in
adenomas, primary colon cancers, and metastases (asterisks mark significant
differences compared with normal mucosa) (B). Typical results for CAR
immunostaining are shown in non-transformed colon mucosa, displaying
CAR localisation at the apical plasma membrane (arrow), whereas in
adenomas additional cytoplasmic CAR immunoreactivity was noted
(arrow). CAR immunoreactivity in primary colon cancers was preferentially
seen in the cytoplasm (arrow), whereas CAR presence at plasma
membrane was frequently lost. In contrast, metastases displayed both
membranous and cytoplasmic CAR presence (C) (magnification:  100,
bar¼200mm).
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sRESULTS
Differential abundance and subcellular distribution of
CAR in colon tissue
We first studied the CAR mRNA expression by quantitative
RT–PCR assays on randomly selected tissue specimens of normal
colon mucosa (n¼10), adenomas (n¼14), primary colon cancers
(n¼15), and colon cancer metastases (n¼13). These studies
showed that the median DCT values for CAR mRNA in comparison
with normal mucosa (0.8805) increased significantly in adenomas
(1.621; P¼0.049), whereas a decrease of CAR mRNA expression
was found in primary colon cancers (0.3920; n.s.) and colon cancer
metastases (0.2040; P¼0.032) (Figure 1A).
Using immunohistochemistry, we then analysed the presence
and histoanatomical distribution of CAR. On a subcellular level,
CAR was found at the plasma membrane of normal mucosa
samples (93%), as well as adenomas and colon cancer metastases
(100% each). Interestingly, membranous CAR immunoreactivity
was found significantly less commonly in primary colon cancers
(49%, Po0.0001). In contrast, the prevalence of cytoplasmic CAR
immunopositivity was increased in adenomas (73%, P¼0.0006),
primary colon cancers (83%, Po0.0001), and metastases (67%,
P¼0.0019), compared with non-neoplastic mucosa (22%) (Figures
1B and C). For a subset of 11 patients, we were able to directly
compare CAR presence in primary cancers and metastasis.
Primary cancers were either entirely CAR negative (n¼4 patients)
or displayed a moderate CAR immunopositivity (mean¼40%
CAR-positive cells). In contrast, metastatic cancers of all patients
were CAR immunopositive.
To assess whether CAR presence and/or subcellular distribution
in colon cancer correlates with clinico-pathological parameters, we
compared the CAR transcription (mRNA levels) and translation
(immunoreactivity) with local tumour growth (T-category), nodal
status (N-category), distant metastases (M-category), tumour
grade (G), lymph (L-category) and blood-vessel-invasion
(V-category), and the UICC tumour stage. None of these
parameters correlated significantly with the expression and
presence of CAR in primary colon cancers (data not shown).
CAR expression in colon cancer cell lines
In permanent colon carcinoma cell lines, FACS revealed the
presence of CAR in all tested cell lines, with comparable CAR
surface manifestation in DLD1, HCT116, and SW480, however,
markedly lower levels in the SW620 cell line (Figure 2A). On the
basis of these findings, we chose all cell lines for both CAR
downregulation and forced expression. Western blotting con-
firmed reduced CAR protein expression in all cell lines after stable
transfection of a CAR-specific siRNA and increased CAR protein
levels following ectopic expression of hCARcDNA (Figure 2B).
Presence of CAR at the surface in these cell lines was assessed by
FACS in unfixed cells. Upon CAR inhibition, a moderate decrease
was noted in the DLD1 cell line and, to a less extent, in HCT116
and SW480. In SW620 cells, no differences were noted. Following
stable expression of CAR, full-length cDNA, a more than 2.5-fold
increase in CAR surface presence was found in DlD1 and SW480
cells, whereas in HCT116 and SW620, a moderate increase was
only found (Figure 2C).
CAR inhibits growth of colon carcinoma cell lines in vitro
and in vivo
To clarify the influence of CAR on the growth of colon cancer cells,
we performed in vitro proliferation assays following ectopic
regulation of CAR expression. The RNAi-mediated functional
CAR knockdown resulted in significantly higher cell numbers in
DLD1 and HCT116 compared with vector controls, whereas for
SW480 and SW620, a minor insignificant increase was found.
Ectopic CAR upregulation resulted in a significant decline of cell
numbers in SW480, SW620, and DLD1 compared with matching
controls, whereas for the HCT116 cell line, no significant
differences were noted (Figure 3). Subcutaneous xenograft
tumours of colon cancer cell lines displayed a markedly reduced
tumour size upon ectopic CAR upregulation compared with
‘vector only’ controls (SW480 (P¼0.02) (Figure 4) and DLD1
(P¼0.11) (data not shown)).
CAR inhibition increases invasion of colon carcinoma cells
The impact of CAR on invasion of colon cancer cells following
blockade of the extracellular portion of CAR was assessed using an
in vitro assay. Incubation with the anti-CAR antibody RmcB,
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Figure 2 CAR expression and ectopic regulation in colon cancer cell
lines. The presence of CAR at the surface was determined by FACS. Data
represent the difference between mean fluorescence intensities (MFI)
measurements for the anti-CAR antibody RmcB and a control containing
the secondary antibody only (A). To regulate CAR expression in colon
cancer cell lines, stable transfections with either a CAR-specific siRNA
(upper panels) or a human full-length CAR expression vector ‘hCARpcD-
NA3.1’ (lower panels) and the respective controls (scrambled [scr] siRNA
or pcDNA3.1) were performed. Differential CAR protein expression was
assessed by western blotting (B) and CAR surface presence was
determined by FACS (C).
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sknown to block CAR, markedly increased the invasiveness into
matrigel of DlD1 and HCT116 cell lines compared with respective
controls. However, SW480 and SW620 did not invade into matrigel
neither with nor without RmcB (Figure 5A).
Loss of CAR facilitates formation of liver metastases
The impact of CAR inhibition on the metastatic behaviour of colon
cancer cells was assessed in 6-week-old female athymic SCID-mice.
At 4 weeks after intrasplenic injection, all those animals displayed
liver metastases, which had received SW480 following siRNA-
mediated CAR knockdown. In contrast, liver metastases were
found in only one animal (14%) injected with SW480 control cells.
Moreover, the number of liver metastases in the group with SW480
siRNA cells was significantly higher (P¼0.0169) (Figure 5B). In
contrast, animals that had received injections of SW620 with
upregulated CAR or controls did not display liver metastases (data
not shown).
CAR facilitates anti-apoptotic effects in colon cancer cells
The potential effect of CAR on the response of colon cancer cells to
apoptotic stimuli was tested by treatment with TRAIL. Hereby,
significantly higher caspase 3/7 levels were found in SW480, DlD1,
and HCT116. In the SW620 cell line, a minor increase was noted
only. Enforced CAR expression led to lower caspase 3/7 activity in
DLD1 cells upon treatment with TRAIL, whereas no changes were
found in HCT116 and SW620, and an increase in the SW480 cell
line was found (data not shown).
DISCUSSION
The current study marks the first report of differential expression
and subcellular distribution of CAR in the adenoma–carcinoma
sequence of colon cancer. Our observations reveal an increase of
CAR mRNA expression in adenomas and a downregulation in
primary cancers and metastasis. On a subcellular level we noted (1)
a significant increase of cytoplasmic CAR in neoplastic tissues
compared with the normal mucosa, (2) reduced CAR presence
at the plasma membrane in primary cancers, and (3) a
‘re-localisation’ of CAR to the plasma membrane in metastatic
tumours. In conjunction with our data regarding the effects of CAR
on growth, invasion, metastasis, and response to apoptotic stimuli,
it may be speculated that CAR facilitates complex, stage-dependent
functions in the course of colon carcinogenesis.
Our finding of high CAR mRNA expression and CAR protein
localisation at the plasma membrane and within the cytoplasm in
adenomas is in line with previous observations in early-stage
breast cancer, Barrett’s oesophagus, and early-stage oesophageal
adenocarcinoma (Anders et al, 2003b; Anders et al, 2003b, 2009a).
Therefore, it may be speculated that high CAR expression marks
are a more general phenomenon in pre- and early malignant
lesions. Functionally, CAR may promote early carcinogenesis as
suggested for cervix and ovarian cancers, with CAR-expressing cell
lines displaying less sensitivity towards apoptotic stimuli (Bruning
et al, 2005). In line with this hypothesis, we found that colon
cancer cell lines become more sensitive towards treatment with
TRAIL following RNAi-mediated functional CAR knockdown.
However, following CAR upregulation, either no change in caspase
activity or contrary results were observed. Therefore, it remains
unclear whether CAR contributes to the suppression of apoptosis
in colonic neoplasias (Tsujitani et al, 1996).
Our observation of reduced CAR mRNA expression and CAR
protein presence at the plasma membrane in primary colon
cancers compared with non-transformed tissue is in agreement
with reports for primary colon cancers and several other
carcinomas (Heideman et al, 2001; Rauen et al, 2002; Sachs et al,
2002; Matsumoto et al, 2005; Korn et al, 2006; Buscarini et al, 2007;
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Figure 3 Influence of CAR on colon cancer cell proliferation. Proliferation was determined in DLD1, HCT116, SW480, and SW620 cells stably
transfected with either a CAR-specific siRNA (upper panels) or a human full-length CAR expression vector ‘hCARpcDNA3.1’ (lower panels) and ‘vector
only’ controls. Data represent typical results from a series of three independent experiments.
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sZhang et al, 2008; Anders et al, 2009b). These findings are highly
suggestive of an entity-independent downregulation of CAR in
primary carcinomas. The loss of CAR at the plasma membrane
may led to an impaired intercellular adhesion as prerequisite for
cancer dissemination as suggested for ovarian, bladder, and gastric
cancers as well as gliomas (Okegawa et al, 2001; Bruning and
Runnebaum, 2004; Huang et al, 2005; Wang et al, 2005; Anders
et al, 2009b). In accordance with this hypothesis, we found that
blocking of the extracellular portion of CAR increases the
invasiveness of colon cancer cells. Furthermore, we observed a
marked rise in the metastatic behaviour of colon cancer cells
following CAR knockdown. These findings are in line with a
previous report showing reduced potential of murine CT26 cells to
form lung metastases (Yamashita et al, 2007). In conjunction with our
observations in human tissues, these data suggest that reduced CAR
expression in primary colon cancers contributes to the spreading of
colon cancer cells and therefore to disease progression.
Furthermore, our findings show that CAR is involved in the
regulation of colon cancer cell proliferation. We noted reduced
growth of colon cancer cells upon ectopic CAR regulation in vitro
and in vivo. In line with these findings, specific CAR silencing led
to complementary effects as shown in vitro. These results are in
agreement with previous observations in gastric, oesophageal,
bladder, and prostate cancer cell lines, as well as glioma cells
(Okegawa et al, 2000, 2001; Huang et al, 2005; Anders et al,
2009a,b), suggesting an entity-independent growth-suppressive
function of CAR in human cancers. Underlying mechanisms,
however, are not fully understood: Previously an accumulation of
p21 and hypophosphorylated retinoblastoma protein upon CAR
upregulation has been detected in human bladder cancer cell lines
(Okegawa et al, 2001). On the basis of these findings, it has been
hypothesised that cell-cell contact, initiated by membrane-bound
CAR, may elicit a negative signal cascade modulating cell cycle
regulators.
In colon cancer metastases, we noted abundant CAR immuno-
positivity confirming findings of a previous study describing
B60% of colon cancer metastases in the liver to express CAR
(Korn et al, 2006). Our findings are also in agreement with
observations in local and distant metastases of prostate cancer,
which present a strong membranous staining comparable to the
non-transformed prostate mucosa, which is also significantly
higher than the one in primary prostate cancers (Rauen et al,
2002). Moreover, these data are in line with findings for the
cytoplasmic TJ protein ZO-1, a known binding partner of CAR
(Kaihara et al, 2003). Our findings also do suggest that CAR
presence at the cell surface of metastatic cancers results from
differential distribution within the cell and not from elevated gene
expression. Whether regulatory pathways such as Raf/MEK/ERK
signalling that has been demonstrated to impact CAR localisation
in colon cancer cells before are involved, remains to be elucidated
(Anders, 2003a). The function of CAR on colon cancer metastases,
however, remains hypothetical. Previously, CAR presence has been
shown to correlate with the state of differentiation in metastatic
colon cancer (Korn et al, 2006). As it has been shown that
colorectal cancers undergo dedifferentiation at the primary site
and ‘re-differentiate’ when metastastic to the liver (Brabletz et al,
2001; Kaihara et al, 2003). Reexpression of CAR may simply
represent an epiphenomenon of cell differentiation. However, CAR
may also be of functional importance as it might allow cancer cells
to gain foothold at the metastatic site, as postulated for E-cadherin
(De Marzo et al, 1999; Rubin et al, 2001; Liu et al, 2002). Recently,
an isoform-specific localisation and regulation of CAR (CAR
Ex7
and CAR
Ex8) has been shown in human airway epithelia. Whether
alternative splicing of the CAR gene occurs and impacts the
development of colonic neoplasia, however, needs to be elucidated
(Excoffon et al, 2010).
In conclusion, our results suggest that CAR mediates promoting
as well as inhibiting functions in colon cancer biology, depending
on the stage of the tumour development and progression.
Interestingly, its inhibitory functions are in contrast to findings
for another member of the TJ family, Claudin 1, which has been
shown to promote cancer growth and metastatic properties
(Dhawan et al, 2005). These findings underline the hypothesis of
complex roles of TJ proteins in the process of colon cancer
development.
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